<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7490914</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">32916466</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">7490914</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">S2213-1582(20)30246-1</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2020.102409</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">102409</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical information for all study participants at baseline (PD: n = 30; HC: n = 15) and for the PD subgroup at baseline and 19.9 ± 3.8 months follow-up (PDFU: n = 15). Independent-samples t-test was used to assess the difference between PD and healthy controls at baseline. For the PD follow-up group, Wilcoxon signed-rank and paired-samples t-test were used to assess the difference between baseline and follow-up.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Demographic and clinical information for all study participants at baseline (<italic>PD: n = 30; HC: n = 15</italic>) and for the PD subgroup at baseline and 19.9 ± 3.8 months follow-up (<italic>PD<sub>FU</sub>: n = 15</italic>). Independent-samples <italic>t-test</italic> was used to assess the difference between PD and healthy controls at baseline. For the PD follow-up group, Wilcoxon signed-rank and paired-samples <italic>t-test</italic> were used to assess the difference between baseline and follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5"><italic>Baseline: PD (n = 30); HC (n = 15)</italic></th></tr><tr><th/><th>PD</th><th>HC</th><th>Statistic</th><th><italic>p</italic></th></tr></thead><tbody><tr><td>Gender (M:F)</td><td>24:6</td><td>8 : 7</td><td/><td/></tr><tr><td>Age (years) <sup>a</sup></td><td>55.4 ± 7.1</td><td>53.15 ± 11.4</td><td><italic>t</italic>(19.674) = 0.696</td><td>0.494</td></tr><tr><td>Disease duration (years) <sup>a</sup></td><td>5.8 ± 2.2</td><td>N/A</td><td/><td/></tr><tr><td>UPDRS-III <sup>a</sup></td><td>31.3 ± 10.6</td><td>N/A</td><td/><td/></tr><tr><td>UPDRS-III Bradykinesia-Rigidity <sup>a</sup></td><td>22.4 ± 8.1</td><td>N/A</td><td/><td/></tr><tr><td>UPDRS-III Tremor <sup>a</sup></td><td>6.2 ± 5.3</td><td>N/A</td><td/><td/></tr><tr><td>Hoehn &amp; Yahr Scale <sup>b</sup></td><td>2.0 (0.0)</td><td>N/A</td><td/><td/></tr><tr><td>LED <sup>a</sup></td><td>670.3 ± 361.8</td><td>N/A</td><td/><td/></tr><tr><td colspan="5">  </td></tr><tr><td colspan="5"><italic>Follow-Up: PD<sub>FU</sub> (n = 15)</italic></td></tr><tr><td/><td>Baseline</td><td>Follow-Up</td><td>Statistic</td><td><italic>p</italic></td></tr><tr><td colspan="5"><hr/></td></tr><tr><td>Gender (M:F)</td><td>12:3</td><td>12:3</td><td/><td/></tr><tr><td>Age (years) <sup>a</sup></td><td>53.0 ± 7.2</td><td>54.7 ± 7.1</td><td><italic>t</italic>(14) = 26.445</td><td>&lt; 0.001 *</td></tr><tr><td>Disease duration (years) <sup>a</sup></td><td>6.0 ± 2.2</td><td>7.7 ± 2.0</td><td><italic>t</italic>(14) = 26.234</td><td>&lt; 0.001 *</td></tr><tr><td>UPDRS-III <sup>a</sup></td><td>31.4 ± 12.0</td><td>35.9 ± 10.9</td><td><italic>t</italic>(14) = 2.003</td><td>0.065</td></tr><tr><td>UPDRS-III Bradykinesia-Rigidity <sup>a</sup></td><td>22.4 ± 9.6</td><td>25.2 ± 8.9</td><td><italic>t</italic>(14) = 1.925</td><td>0.075</td></tr><tr><td>UPDRS-III Tremor <sup>a</sup></td><td>6.9 ± 4.5</td><td>8.3 ± 4.2</td><td><italic>t</italic>(14) = 1.514</td><td>0.152</td></tr><tr><td>Hoehn &amp; Yahr Scale <sup>b</sup></td><td>2.0 (0.0)</td><td>2.0 (0.0)</td><td><italic>Z</italic> = 1.7</td><td>0.083</td></tr><tr><td>LED <sup>a</sup></td><td>771.7 ± 386.5</td><td>906.3 ± 235.7</td><td><italic>t</italic>(14) = 2.156</td><td>0.046 *</td></tr></tbody></table><table-wrap-foot><fn id="sp0065"><p><italic><sup>a</sup></italic> Data are presented as Mean ± SD.</p></fn><fn id="sp0070"><p><italic><sup>b</sup></italic> Data are presented as Median (Interquartile Range).</p></fn><fn id="sp0075"><p>* Indicates <italic>p</italic> &lt; 0.05</p></fn><fn id="sp0080"><p>LED = L-dopa equivalent dose (mg).</p></fn><fn id="sp0085"><p>UPDRS = Unified Parkinson’s disease rating scale.</p></fn><fn id="sp0090"><p>The UPDRS and H&amp;Y scale were assessed in the practically defined off-medication state.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical information for all study participants at baseline (PD: n = 30; HC: n = 15) and for the PD subgroup at baseline and 19.9 ± 3.8 months follow-up (PDFU: n = 15). Independent-samples t-test was used to assess the difference between PD and healthy controls at baseline. For the PD follow-up group, Wilcoxon signed-rank and paired-samples t-test were used to assess the difference between baseline and follow-up.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Baseline: PD (n = 30); HC (n = 15)</th></tr><tr><th/><th>PD</th><th>HC</th><th>Statistic</th><th>p</th></tr></thead><tbody><tr><td>Gender (M:F)</td><td>24:6</td><td>8 : 7</td><td/><td/></tr><tr><td>Age (years) a</td><td>55.4 ± 7.1</td><td>53.15 ± 11.4</td><td>t(19.674) = 0.696</td><td>0.494</td></tr><tr><td>Disease duration (years) a</td><td>5.8 ± 2.2</td><td>N/A</td><td/><td/></tr><tr><td>UPDRS-III a</td><td>31.3 ± 10.6</td><td>N/A</td><td/><td/></tr><tr><td>UPDRS-III Bradykinesia-Rigidity a</td><td>22.4 ± 8.1</td><td>N/A</td><td/><td/></tr><tr><td>UPDRS-III Tremor a</td><td>6.2 ± 5.3</td><td>N/A</td><td/><td/></tr><tr><td>Hoehn &amp; Yahr Scale b</td><td>2.0 (0.0)</td><td>N/A</td><td/><td/></tr><tr><td>LED a</td><td>670.3 ± 361.8</td><td>N/A</td><td/><td/></tr><tr><td colspan="5">  </td></tr><tr><td colspan="5">Follow-Up: PDFU (n = 15)</td></tr><tr><td/><td>Baseline</td><td>Follow-Up</td><td>Statistic</td><td>p</td></tr><tr><td colspan="5"/></tr><tr><td>Gender (M:F)</td><td>12:3</td><td>12:3</td><td/><td/></tr><tr><td>Age (years) a</td><td>53.0 ± 7.2</td><td>54.7 ± 7.1</td><td>t(14) = 26.445</td><td>&lt; 0.001 *</td></tr><tr><td>Disease duration (years) a</td><td>6.0 ± 2.2</td><td>7.7 ± 2.0</td><td>t(14) = 26.234</td><td>&lt; 0.001 *</td></tr><tr><td>UPDRS-III a</td><td>31.4 ± 12.0</td><td>35.9 ± 10.9</td><td>t(14) = 2.003</td><td>0.065</td></tr><tr><td>UPDRS-III Bradykinesia-Rigidity a</td><td>22.4 ± 9.6</td><td>25.2 ± 8.9</td><td>t(14) = 1.925</td><td>0.075</td></tr><tr><td>UPDRS-III Tremor a</td><td>6.9 ± 4.5</td><td>8.3 ± 4.2</td><td>t(14) = 1.514</td><td>0.152</td></tr><tr><td>Hoehn &amp; Yahr Scale b</td><td>2.0 (0.0)</td><td>2.0 (0.0)</td><td>Z = 1.7</td><td>0.083</td></tr><tr><td>LED a</td><td>771.7 ± 386.5</td><td>906.3 ± 235.7</td><td>t(14) = 2.156</td><td>0.046 *</td></tr></tbody></table></div>a Data are presented as Mean ± SD.b Data are presented as Median (Interquartile Range).* Indicates p &lt; 0.05LED = L-dopa equivalent dose (mg).UPDRS = Unified Parkinson’s disease rating scale.The UPDRS and H&amp;Y scale were assessed in the practically defined off-medication state.</transformed-table></extracted-table><extracted-table><table-id>t0010</table-id><table-label>Table 2</table-label><table-caption>Clusters showing positive correlations between posterior putamen functional connectivity and 11C-PE2I BPND and disease severity (Bradykinesia-Rigidity sub-score), as revealed by voxel-wise multiple regression analysis for all PD patients. Longitudinal multiple regression using difference maps (Δ: follow-up – baseline) from the PDFU group are also shown.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0010"><label>Table 2</label><caption><p>Clusters showing positive correlations between posterior putamen functional connectivity and <sup>11</sup>C-PE2I BP<sub>ND</sub> and disease severity (Bradykinesia-Rigidity sub-score), as revealed by voxel-wise multiple regression analysis for all PD patients. Longitudinal multiple regression using difference maps (Δ: follow-up – baseline) from the PD<sub>FU</sub> group are also shown.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Seed</th><th rowspan="2"/><th rowspan="2">Covariate of Interest</th><th colspan="2">Cluster<hr/></th><th rowspan="2">Peak <italic>T</italic></th><th colspan="3">MNI Coordinates<hr/></th><th rowspan="2">Brain Region</th></tr><tr><th><italic>p</italic> Value*</th><th><italic>k</italic></th><th><italic>x</italic></th><th><italic>y</italic></th><th><italic>z</italic></th></tr></thead><tbody><tr><td rowspan="5">Posterior putamen</td><td>Baseline Analysis(n = 30)</td><td><sup>11</sup>C-PE2I BP<sub>ND</sub></td><td>0.027</td><td>22</td><td>4.65</td><td>0</td><td>−18</td><td>−12</td><td>Midbrain</td></tr><tr><td rowspan="4">Follow-up Analysis(n = 15)</td><td rowspan="3">Δ <sup>11</sup>C-PE2I BP<sub>ND</sub></td><td>0.007</td><td>580</td><td>5.37</td><td>−4</td><td>−26</td><td>−8</td><td>Midbrain, extending into thalamus</td></tr><tr><td>0.001</td><td>845</td><td>4.66</td><td>10</td><td>−4</td><td>72</td><td>Supplementary motor area</td></tr><tr><td>0.031</td><td>376</td><td>4.39</td><td>−36</td><td>−36</td><td>54</td><td>Postcentral gyrus, extending into precentral gyrus</td></tr><tr><td>Δ Bradykinesia-Rigidity sub-score</td><td>0.032</td><td>48</td><td>6.37</td><td>24</td><td>6</td><td>−10</td><td>Posterior putamen</td></tr></tbody></table><table-wrap-foot><fn id="sp0100"><p>Threshold of <italic>p</italic> &lt; 0.001 uncorrected at voxel-level and <italic>p</italic> &lt; 0.05 corrected for false discovery rate at cluster-level.</p></fn><fn id="sp0105"><p>Coordinates of peak voxels (<italic>x, y, z</italic>) are given in Montreal Neurologic Institute (MNI) space.</p></fn><fn id="sp0110"><p>*Indicates correction for false discovery rate.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Clusters showing positive correlations between posterior putamen functional connectivity and 11C-PE2I BPND and disease severity (Bradykinesia-Rigidity sub-score), as revealed by voxel-wise multiple regression analysis for all PD patients. Longitudinal multiple regression using difference maps (Δ: follow-up – baseline) from the PDFU group are also shown.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Seed</th><th rowspan="2"/><th rowspan="2">Covariate of Interest</th><th colspan="2">Cluster</th><th rowspan="2">Peak T</th><th colspan="3">MNI Coordinates</th><th rowspan="2">Brain Region</th></tr><tr><th>p Value*</th><th>k</th><th>x</th><th>y</th><th>z</th></tr></thead><tbody><tr><td rowspan="5">Posterior putamen</td><td>Baseline Analysis(n = 30)</td><td>11C-PE2I BPND</td><td>0.027</td><td>22</td><td>4.65</td><td>0</td><td>−18</td><td>−12</td><td>Midbrain</td></tr><tr><td rowspan="4">Follow-up Analysis(n = 15)</td><td rowspan="3">Δ 11C-PE2I BPND</td><td>0.007</td><td>580</td><td>5.37</td><td>−4</td><td>−26</td><td>−8</td><td>Midbrain, extending into thalamus</td></tr><tr><td>0.001</td><td>845</td><td>4.66</td><td>10</td><td>−4</td><td>72</td><td>Supplementary motor area</td></tr><tr><td>0.031</td><td>376</td><td>4.39</td><td>−36</td><td>−36</td><td>54</td><td>Postcentral gyrus, extending into precentral gyrus</td></tr><tr><td>Δ Bradykinesia-Rigidity sub-score</td><td>0.032</td><td>48</td><td>6.37</td><td>24</td><td>6</td><td>−10</td><td>Posterior putamen</td></tr></tbody></table></div>Threshold of p &lt; 0.001 uncorrected at voxel-level and p &lt; 0.05 corrected for false discovery rate at cluster-level.Coordinates of peak voxels (x, y, z) are given in Montreal Neurologic Institute (MNI) space.*Indicates correction for false discovery rate.</transformed-table></extracted-table></extracted-tables-set>